Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26914874 | 0.84 | NR1H2 (0.39) | KMT2AMEN1PTPN1GRM5NR1H2 | |
| SCHEMBL29264471 | 0.83 | ABHD6 (0.37) | ABHD6 | |
| SCHEMBL24602686 | 0.81 | MEN1 (0.43) | ABHD6KMT2AMEN1PTPN1ESR2 | |
| SCHEMBL24602685 | 0.81 | ABHD6 (0.42) | ABHD6KMT2AMEN1PTPN1ESR2 | |
| SCHEMBL30685431 | 0.81 | MEN1 (0.43) | ABHD6KMT2AMEN1PTPN1ESR2 | |
| SCHEMBL26914877 | 0.80 | ABHD6 (0.41) | ABHD6KMT2AMEN1PTPN1ESR2 | |
| SCHEMBL31621607 | 0.80 | ABHD6 (0.44) | ABHD6KMT2AMEN1PTPN1ESR2 | |
| SCHEMBL31621630 | 0.80 | ABHD6 (0.44) | ABHD6KMT2AMEN1PTPN1ESR2 | |
| SCHEMBL26914843 | 0.80 | MEN1 (0.47) | ABHD6KMT2AMEN1PTPN1ESR2 | |
| SCHEMBL24602711 | 0.79 | MEN1 (0.41) | ABHD6KMT2AMEN1PTPN1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-116848122-A | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022166845-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | F2, PLG, PLAT | ABHD6 2535/4885KMT2A 2898/4885MEN1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.